56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting
The DOI matches its Crossref record.
Abstract
The contributions of glucose-dependent insulinotropic polypeptide (GIP) to overall metabolic and weight effects of incretin therapies are unclear. Weight loss efficacy has been observed with glucagon-like peptide 1 (GLP-1) and GIP receptor agonist tirzepatide, but weight loss efficacy has also been observed with GLP-1 agonism mixed with GIP antagonism. LY3537021 (LY), a selective, long-acting GIP receptor agonist, was tested in single [SAD, LY vs placebo (PBO)] and multiple ascending doses (MAD, LY vs PBO once weekly for 4 weeks) to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics. In SAD, healthy participants (N=39) had a mean age of 43.5 yrs and mean weight of 74.4 kg. People with T2D (N=6) had a mean age of 58.5 yrs and mean weight of 75.1 kg. Median Tmax was 12 to 84 hrs post dose and mean terminal T½ was approximately 11 to 14 days. PK in people with T2D appeared comparable to healthy participants. In MAD, healthy participants (N=18) had a mean age of 38.3 yrs and mean weight of 75.4 kg. People with T2D (N=18) had a mean age of 57.1 yrs and mean weight of 74.3 kg. In healthy MAD participants at day 57, numerically greater mean weight loss was reported in those who received LY (-1.1 to -2.2 kg) versus PBO (-0.4 kg). In people with T2D, numerically greater mean weight loss was reported for those receiving LY (-1.9 to -3.1 kg) versus PBO (-0.4 kg). LY did not result in gastric emptying delay. No serious adverse events or hypoglycemia occurred. Study participants had few mild gastrointestinal (GI) adverse events. Study findings included decreased appetite (LY: n=4, PBO: n=1), abdominal pain (LY: n=1, PBO: n=0) and diarrhea (LY: n=1, PBO: n=2). No nausea or vomiting was observed. Repeated dosing of a long-acting GIP receptor agonist, once weekly for 4 weeks, induced weight loss without gastric emptying delay or nausea and vomiting. The results suggest that GIP agonism can contribute to weight loss effects seen with multi-agonist incretins such as tirzepatide. Disclosure: F.K.Knop: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi, Consultant; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi, Research Support; Novo Nordisk, Zealand Pharma A/S, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi, Lundbeck. S.Urva: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. M.Rettiganti: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. C.Benson: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. W.Roell: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. K.J.Mather: Employee; Eli Lilly and Company. A.Haupt: Employee; Lilly, Stock/Shareholder; Lilly. E.J.Pratt: Employee; Eli Lilly and Company.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a recent phase 1 clinical trial with a long-acting GIP RA found that repeated dosing for 4 weeks induced modest WL (−1.9 to −3.1 kg vs. −0.4 kg with placebo) in people with T2D, without delay in gastric emptying or nausea and vomiting [37].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [37]
Citations
Cited by
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“…anorexigenic action of GIP receptor agonism [36] and a recent phase 1 clinical trial with a long-acting GIP RA found that repeated dosing for 4 weeks induced modest WL ( − 1.9 to − 3.1 kg vs. − 0.4 kg with placebo) in people with T2D, without delay in gastric emptying or nausea and vomiting [37].”
InfluentialRegmi, A., Aihara, E., Christe, M. E., Varga, G., Beyer, T. P., Ruan, X., Beebe, E., O’Farrell, L. S., Bellinger, M. A., Austin, A. K., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.010 · Cited by 130
Self-citationLiskiewicz, A., Khalil, A., Liskiewicz, D., Novikoff, A., Grandl, G., Maity-Kumar, G., Gutgesell, R. M., Bakhti, M., Bastidas-Ponce, A., Czarnecki, O., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00931-7 · Cited by 110
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
Yu, X., Chen, S., Funcke, J.-B., Straub, L. G., Pirro, V., Emont, M. P., Droz, B. A., Collins, K. A., Joung, C., Pearson, M. J., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.003 · Cited by 67
Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15875 · Cited by 41
Self-citationGasbjerg, L. S., Rosenkilde, M. M., Meier, J. J., Holst, J. J., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15216 · Cited by 41
“68 The molecular details or any other data from the clinical studies with the two GIP receptor agonists have not been disclosed.”
BackgroundSelf-citationNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Gasbjerg, L. S., Rasmussen, R. S., Dragan, A., Lindquist, P., Melchiorsen, J. U., Stępniewski, T. M., Schiellerup, S. P., Tordrup, E. K., Gadgaard, S., Kizilkaya, H. S., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16478 · Cited by 34
A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice
Douros, J. D., Novikoff, A., DUBOIS, B. N., Rohlfs, R., Mokrosiński, J., Hogendorf, W. F. J., Augustin, R., Merkestein, M., Martini, L. B. E., Linderoth, L., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102124 · Cited by 25
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
ROSENKILDE, M. M., Lindquist, P., Kizilkaya, H. S., & Gasbjerg, L. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171212 · Cited by 22
“This mechanism has also been proposed to contribute to the therapeutic beneficial effects of antagonistic antibodies targeting the GIPR [23,71,74].”
BackgroundTherapeutic Targeting of the GIP Receptor—Revisiting the Controversies
Campbell, J. E., & Drucker, D. J. (2025) · Diabetes · doi:10.2337/db25-0393 · Cited by 22
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
Davies, I., Adriaenssens, A. E., Scott, W. R., Carling, D., Murphy, K. G., MINNION, J. S., Bloom, S. R., Jones, B. J., & Tan, T. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102094 · Cited by 20
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
“The translational relevance of these findings is highlighted by studies in people with obesity and T2D showing that GIPR agonism reduces body weight and attenuates nausea and emesis induced by a GLP-1R agonist (62,63).”
Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease
Sangwung, P., Ho, J. D., Siddall, T., Lin, J., Tomás, A., Jones, B. J., & Sloop, K. W. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00371.2023 · Cited by 15
Douros, J. D., Mowery, S. A., & Knerr, P. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113812 · Cited by 12
“This finding appears to translate to humans given that the GIPR mono-agonist LY3537021 has been reported to reduce body weight in healthy volunteers and patients with T2D [15].”
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Incretins and Development of Incretin‐based Therapeutics
Zheng, N., Su, X., Zhang, S., & Shen, W. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch09 · Cited by 6
Metformin Boosts Intestinal Lipid Sensing via GIP to Suppress Feeding
Kuah, R., Wang, M. T., Yang, Z., Back, G., Li, R., Bruce, K., LoChoy, J. N., Beaudry, J. L., Barros, D. R., Zhang, S., et al. (2025) · Diabetes · doi:10.2337/db25-0100 · Cited by 5
Safety of native glucose-dependent insulinotropic polypeptide in humans
Helsted, M. M., Schaltz, N. L., Gasbjerg, L. S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2024) · Peptides · doi:10.1016/j.peptides.2024.171214 · Cited by 3
Self-citationFuture Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
Manchanda, Y., Desoki, R., Gardner, E. J., Perry, J. R. B., Wainscott, D. B., Stutsman, C., Langenberg, C., Coghlan, M. P., Bhatnagar, P., Ho, J. D., et al. (2025) · medRxiv · doi:10.1101/2025.08.15.25333807
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Zhang, S., Liu, S., Zhou, M., Wang, J., Zhang, Y., Zhong, H., & Ning, G. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06090-6
“This uncertainty has hindered the clinical translation of stable GIPRA candidates, causing most patients to remain at the early preclinical research stage without progressing to clinical development [84].”
Manchanda, Y., Desoki, R., Gardner, E. J., Perry, J. R. B., Wainscott, D. B., Stutsman, C., Langenberg, C., Coghlan, M. P., Bhatnagar, P., Ho, J. D., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec3372
“…may be due to G protein–biased agonism at the GLP-1R ( 59 ), several rodent studies have demonstrated the potential for weight loss with GIPR mono-agonism ( 7 , 60 , 61 ), and recent works show that long-acting GIPR agonists can drive a moderate degree of weight loss in humans ( 62 , 63 ).”
Metadata
- Authors
- KNOP, F. K., URVA, S., RETTIGANTI, M., BENSON, C., ROELL, W., MATHER, K. J., HAUPT, A., & PRATT, E. J.
- Affiliations
- Hellerup, Denmark, Indianapolis, IN
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2023-06-20
- Volume
- 72
- Issue
- Supplement_1
- ISSN
- 0012-1797 (ISSN-L)
- OpenAlex
- W4381337151
- Cited by
- 29
- References
- 0
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 11 · 2023: 2
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GIP receptor agonist, weight loss, type 2 diabetes, pharmacokinetics, pharmacodynamics, nausea and vomiting, gastric emptying, appetite, gastrointestinal adverse effects, safety and tolerability, multiple ascending dose, single ascending dose, hypoglycemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.